SimpleXMLElement Object ( [PubmedArticle] => SimpleXMLElement Object ( [MedlineCitation] => SimpleXMLElement Object ( [@attributes] => Array ( [Status] => In-Data-Review [Owner] => NLM ) [PMID] => 33009870 [DateRevised] => SimpleXMLElement Object ( [Year] => 2020 [Month] => 11 [Day] => 25 ) [Article] => SimpleXMLElement Object ( [@attributes] => Array ( [PubModel] => Print-Electronic ) [Journal] => SimpleXMLElement Object ( [ISSN] => 1545-5017 [JournalIssue] => SimpleXMLElement Object ( [@attributes] => Array ( [CitedMedium] => Internet ) [Volume] => 68 [Issue] => 1 [PubDate] => SimpleXMLElement Object ( [Year] => 2021 [Month] => Jan ) ) [Title] => Pediatric blood & cancer [ISOAbbreviation] => Pediatr Blood Cancer ) [ArticleTitle] => Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma. [Pagination] => SimpleXMLElement Object ( [MedlinePgn] => e28741 ) [ELocationID] => 10.1002/pbc.28741 [Abstract] => SimpleXMLElement Object ( [AbstractText] => Array ( [0] => Pediatric papillary thyroid carcinoma (PTC) is clinically and biologically distinct from adult PTC. We sequenced a cohort of clinically annotated pediatric PTC cases enriched for high-risk tumors to identify genetic alterations of relevance for diagnosis and therapy. [1] => Tumor DNA and RNA were extracted from FFPE tissue and subjected to next-generation sequencing (NGS) library preparation using a custom 124-gene hybridization capture panel and the 75-gene Archer Oncology Research Panel, respectively. NGS libraries were sequenced on an Illumina MiSeq. [2] => Thirty-six pediatric PTC cases were analyzed. Metastases were frequently observed to cervical lymph nodes (29/36, 81%), with pulmonary metastases less commonly found (10/36, 28%). Relapsed or refractory disease occurred in 18 patients (18/36, 50%). DNA sequencing revealed targetable mutations in 8 of 31 tumors tested (26%), most commonly BRAF p.V600E (n = 6). RNA sequencing identified targetable fusions in 13 of 25 tumors tested (52%): RET (n = 8), NTRK3 (n = 4), and BRAF. Mutually exclusive targetable alterations were discovered in 15 of the 20 tumors (75%) with both DNA and RNA analyzed. Fusion-positive PTC was associated with multifocal disease, higher tumor staging, and higher American Thyroid Association risk levels. Both BRAF V600E mutations and gene fusions were correlated with the presence of cervical metastases. [3] => Targetable alterations were identified in 75% of pediatric PTC cases with both DNA and RNA evaluated. Inclusion of RNA sequencing for detection of fusion genes is critical for evaluation of these tumors. Patients with fusion-positive tumors were more likely to have features of high-risk disease. ) [CopyrightInformation] => © 2020 Wiley Periodicals LLC. ) [AuthorList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Author] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Potter [ForeName] => Samara L [Initials] => SL [Identifier] => https://orcid.org/0000-0001-7122-953X [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Reuther [ForeName] => Jacquelyn [Initials] => J [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) ) ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Chandramohan [ForeName] => Raghu [Initials] => R [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. ) ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Gandhi [ForeName] => Ilavarasi [Initials] => I [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Hollingsworth [ForeName] => Faith [Initials] => F [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) ) [5] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Sayeed [ForeName] => Hadi [Initials] => H [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) ) [6] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Voicu [ForeName] => Horatiu [Initials] => H [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) ) [7] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Kakkar [ForeName] => Nipun [Initials] => N [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) ) [8] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Baksi [ForeName] => Koel Sen [Initials] => KS [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) ) [9] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Sarabia [ForeName] => Stephen F [Initials] => SF [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) ) [10] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Lopez [ForeName] => Monica E [Initials] => ME [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Department of Surgery, Texas Children's Hospital, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. ) ) ) [11] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Chelius [ForeName] => Daniel C [Initials] => DC [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Department of Surgery, Texas Children's Hospital, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas. ) [2] => SimpleXMLElement Object ( [Affiliation] => Department of Otolaryngology, Baylor College of Medicine, Houston, Texas. ) ) ) [12] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Athanassaki [ForeName] => Ioanna D [Initials] => ID [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Pediatric Endocrinology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas. ) ) [13] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Mahajan [ForeName] => Priya [Initials] => P [Identifier] => https://orcid.org/0000-0002-6710-5865 [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) ) [14] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Venkatramani [ForeName] => Rajkumar [Initials] => R [Identifier] => https://orcid.org/0000-0002-4785-106X [AffiliationInfo] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) ) [15] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Quintanilla [ForeName] => Norma M [Initials] => NM [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) ) ) [16] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Lopez-Terrada [ForeName] => Dolores H [Initials] => DH [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) [2] => SimpleXMLElement Object ( [Affiliation] => The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. ) ) ) [17] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Roy [ForeName] => Angshumoy [Initials] => A [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) [2] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology, Texas Children's Hospital, Houston, Texas. ) [3] => SimpleXMLElement Object ( [Affiliation] => The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. ) ) ) [18] => SimpleXMLElement Object ( [@attributes] => Array ( [ValidYN] => Y ) [LastName] => Parsons [ForeName] => D Williams [Initials] => DW [AffiliationInfo] => Array ( [0] => SimpleXMLElement Object ( [Affiliation] => Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas. ) [1] => SimpleXMLElement Object ( [Affiliation] => Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. ) [2] => SimpleXMLElement Object ( [Affiliation] => Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. ) [3] => SimpleXMLElement Object ( [Affiliation] => The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. ) ) ) ) ) [Language] => eng [GrantList] => SimpleXMLElement Object ( [@attributes] => Array ( [CompleteYN] => Y ) [Grant] => Array ( [0] => SimpleXMLElement Object ( [Agency] => Paul Calabresi Scholar K12 Career Development Award [Country] => SimpleXMLElement Object ( ) ) [1] => SimpleXMLElement Object ( [Agency] => St. Baldrick's Foundation [Country] => SimpleXMLElement Object ( ) ) [2] => SimpleXMLElement Object ( [Agency] => Gillson Longenbaugh Foundation [Country] => SimpleXMLElement Object ( ) ) ) ) [PublicationTypeList] => SimpleXMLElement Object ( [PublicationType] => Journal Article ) [ArticleDate] => SimpleXMLElement Object ( [@attributes] => Array ( [DateType] => Electronic ) [Year] => 2020 [Month] => 10 [Day] => 03 ) ) [MedlineJournalInfo] => SimpleXMLElement Object ( [Country] => United States [MedlineTA] => Pediatr Blood Cancer [NlmUniqueID] => 101186624 [ISSNLinking] => 1545-5009 ) [CitationSubset] => IM [KeywordList] => SimpleXMLElement Object ( [@attributes] => Array ( [Owner] => NOTNLM ) [Keyword] => Array ( [0] => BRAF V600E [1] => NTRK fusions [2] => RET fusions [3] => genomics [4] => papillary thyroid carcinoma [5] => pediatric thyroid cancer ) ) ) [PubmedData] => SimpleXMLElement Object ( [History] => SimpleXMLElement Object ( [PubMedPubDate] => Array ( [0] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => received ) [Year] => 2020 [Month] => 06 [Day] => 04 ) [1] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => revised ) [Year] => 2020 [Month] => 08 [Day] => 07 ) [2] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => accepted ) [Year] => 2020 [Month] => 09 [Day] => 10 ) [3] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => pubmed ) [Year] => 2020 [Month] => 10 [Day] => 4 [Hour] => 6 [Minute] => 0 ) [4] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => medline ) [Year] => 2020 [Month] => 10 [Day] => 4 [Hour] => 6 [Minute] => 0 ) [5] => SimpleXMLElement Object ( [@attributes] => Array ( [PubStatus] => entrez ) [Year] => 2020 [Month] => 10 [Day] => 3 [Hour] => 8 [Minute] => 33 ) ) ) [PublicationStatus] => ppublish [ArticleIdList] => SimpleXMLElement Object ( [ArticleId] => Array ( [0] => 33009870 [1] => 10.1002/pbc.28741 ) ) [ReferenceList] => SimpleXMLElement Object ( [Title] => REFERENCES [Reference] => Array ( [0] => SimpleXMLElement Object ( [Citation] => Cordioli MI, Moraes L, Bastos AU, et al. Fusion oncogenes are the main genetic events found in sporadic papillary thyroid carcinomas from children. Thyroid. 2017;27(2):182-188. ) [1] => SimpleXMLElement Object ( [Citation] => Lee YA, Jung HW, Kim HY, et al. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years. J Clin Endocrinol Metab. 2015;100(4):1619-1629. ) [2] => SimpleXMLElement Object ( [Citation] => Vergamini LB, Frazier AL, Abrantes FL, Ribeiro KB, Rodriguez-Galindo C. Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J Pediatr. 2014;164(6):1481-1485. ) [3] => SimpleXMLElement Object ( [Citation] => Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res. 2009;156(1):167-172. ) [4] => SimpleXMLElement Object ( [Citation] => Mostoufi-Moab S, Barakat LP, Bauer AJ. Quality of life in adolescent patients with differentiated thyroid cancer: moving beyond survival. J Clin Endocrinol Metab. 2012;97(10):3453-3456. ) [5] => SimpleXMLElement Object ( [Citation] => Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159(3):676-690. ) [6] => SimpleXMLElement Object ( [Citation] => Bauer AJ. Molecular genetics of thyroid cancer in children and adolescents. Endocrinol Metab Clin North Am. 2017;46(2):389-403. ) [7] => SimpleXMLElement Object ( [Citation] => Alzahrani AS, Murugan AK, Qasem E, Alswailem M, Al-Hindi H, Shi Y. Single point mutations in pediatric differentiated thyroid cancer. Thyroid. 2017;27(2):189-196. ) [8] => SimpleXMLElement Object ( [Citation] => Vanden Borre P, Schrock AB, Anderson PM, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist. 2017;22(3):255-263. ) [9] => SimpleXMLElement Object ( [Citation] => Sassolas G, Hafdi-Nejjari Z, Ferraro A, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid. 2012;22(1):17-26. ) [10] => SimpleXMLElement Object ( [Citation] => Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope. 2014;124(9):E389-393. ) [11] => SimpleXMLElement Object ( [Citation] => Mostoufi-Moab S, Labourier E, Sullivan L, et al. Molecular testing for oncogenic gene alterations in pediatric thyroid lesions. Thyroid. 2018;28(1):60-67. ) [12] => SimpleXMLElement Object ( [Citation] => Picarsic JL, Buryk MA, Ozolek J, et al. Molecular characterization of sporadic pediatric thyroid carcinoma with the DNA/RNA ThyroSeq v2 next-generation sequencing assay. Pediatr Dev Pathol. 2016;19(2):115-122. ) [13] => SimpleXMLElement Object ( [Citation] => Prasad ML, Vyas M, Horne MJ. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122(7):1097-1107. ) [14] => SimpleXMLElement Object ( [Citation] => Ricarte-Filho JC, Li S, Garcia-Rendueles ME, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest. 2013;123(11):4935-4944. ) [15] => SimpleXMLElement Object ( [Citation] => Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid. 2005;15(4):320-325. ) [16] => SimpleXMLElement Object ( [Citation] => Oishi N, Kondo T, Nakazawa T, et al. Frequent BRAF (V600E) and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan. Endocr Pathol. 2017;28(2):103-111. ) [17] => SimpleXMLElement Object ( [Citation] => Ballester LY, Sarabia SF, Sayeed H, et al. Integrating molecular testing in the diagnosis and management of children with thyroid lesions. Pediatr Dev Pathol. 2016;19(2):94-100. ) [18] => SimpleXMLElement Object ( [Citation] => Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716-759. ) [19] => SimpleXMLElement Object ( [Citation] => Texas Children's Pediatric Solid Tumor Cancer Mutation Panel. http://pathology.texaschildrens.org/catalog/mddetail27.asp?TestCode=CMPTIS&COption=ALL. Accessed August 1, 2020. ) [20] => SimpleXMLElement Object ( [Citation] => Texas Children's Pediatric Solid Tumor RNA Fusion Panel. http://pathology.texaschildrens.org/catalog/mddetail27.asp?TestCode=PSDB9578&COption=ALL. Accessed August 1, 2020. ) [21] => SimpleXMLElement Object ( [Citation] => Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589-595. ) [22] => SimpleXMLElement Object ( [Citation] => Picard. http://broadinstitute.github.io/picard/. Accessed August 1, 2020. ) [23] => SimpleXMLElement Object ( [Citation] => Rimmer A, Phan H, Mathieson I, et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet. 2014;46(8):912-918. ) [24] => SimpleXMLElement Object ( [Citation] => McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122. ) [25] => SimpleXMLElement Object ( [Citation] => Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 2016;12(4):e1004873. ) [26] => SimpleXMLElement Object ( [Citation] => Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24(13):3059-3068. ) [27] => SimpleXMLElement Object ( [Citation] => Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008;27(42):5648-5650. ) [28] => SimpleXMLElement Object ( [Citation] => Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885-4893. ) [29] => SimpleXMLElement Object ( [Citation] => Henke LE, Perkins SM, Pfeifer JD, et al. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer. 2014;61(7):1168-1172. ) [30] => SimpleXMLElement Object ( [Citation] => Nikita ME, Jiang W, Cheng SM, et al. Mutational analysis in pediatric thyroid cancer and correlations with age, ethnicity, and clinical presentation. Thyroid. 2016;26(2):227-234. ) [31] => SimpleXMLElement Object ( [Citation] => Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31(3):463-473. ) [32] => SimpleXMLElement Object ( [Citation] => Tannenbaum-Dvir S, Glade Bender JL, Church AJ, et al. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud. 2015;1(1):a000471. ) [33] => SimpleXMLElement Object ( [Citation] => Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):775-788. ) [34] => SimpleXMLElement Object ( [Citation] => Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;78(2):279-290. ) [35] => SimpleXMLElement Object ( [Citation] => Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272-1282. ) [36] => SimpleXMLElement Object ( [Citation] => Dadu R, Shah K, Busaidy NL, et al. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015;100(1):E77-81. ) [37] => SimpleXMLElement Object ( [Citation] => Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: a phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer. 2018;65(5):e26947. ) [38] => SimpleXMLElement Object ( [Citation] => Aguilera D, Janss A, Mazewski C, et al. Successful retreatment of a child with a refractory brainstem ganglioglioma with vemurafenib. Pediatr Blood Cancer. 2016;63(3):541-543. ) [39] => SimpleXMLElement Object ( [Citation] => Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61(6):1101-1103. ) [40] => SimpleXMLElement Object ( [Citation] => van Tilburg CM, Selt F, Sahm F, et al. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. Pediatr Blood Cancer. 2018;65(3):e26893. https://doi.org/10.1002/pbc.26893 ) [41] => SimpleXMLElement Object ( [Citation] => Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. ) [42] => SimpleXMLElement Object ( [Citation] => Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705-714. ) [43] => SimpleXMLElement Object ( [Citation] => Roskoski R Jr, Sadeghi-Nejad A. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res. 2018;128:1-17. ) [44] => SimpleXMLElement Object ( [Citation] => Kim A, Widemann BC, Krailo M, et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62(9):1562-1566. ) [45] => SimpleXMLElement Object ( [Citation] => Mahajan P, Dawrant J, Kheradpour A, et al. Response to lenvatinib in children with papillary thyroid carcinoma. Thyroid. 2018;28(11):1450-1454. ) [46] => SimpleXMLElement Object ( [Citation] => ClinicalTrials.gov. Identifier NCT03157128: Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). Bethesda (MD); 2018. ) [47] => SimpleXMLElement Object ( [Citation] => ClinicalTrials.gov. Identifier NCT03155620: Targeted therapy directed by genetic testing in treating pediatric patients with relapsed or refractory advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders (The Pediatric MATCH Screening Trial). Bethesda, MD; 2017. ) [48] => SimpleXMLElement Object ( [Citation] => Hillier K, Hughes A, Shamberger RC, et al. A novel ALK fusion in pediatric medullary thyroid carcinoma. Thyroid. 2019;29(11):1704-1707. ) ) ) ) ) ) Koel Sen Baksi | PubFacts

Publications by authors named "Koel Sen Baksi"